Antibody persistence after two vaccinations with either FSME-IMMUN® Junior or ENCEPUR® Children followed by third vaccination with FSME-IMMUN® Junior

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 6, 2012, Pages 736-742

  Prymula, Roman ^a   Pöllabauer, Eva Maria ^b   Pavlova, Borislava G ^b   Löw Baselli, Alexandra ^b   Fritsch, Sandor ^b   Angermayr, Rudolf ^c   Geisberger, Alexander ^b   Barrett, P Noel ^b   Ehrlich, Hartmut J ^b  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b BAXTER BIOSCIENCE   (Austria)

^c General Practice   (Austria)

Author keywords

Encepur Children; FSME IMMUN Junior; Pediatric vaccines; Tick borne encephalitis

Indexed keywords

ENCEPUR CHILDREN; FSME IMMUN JUNIOR; NEUTRALIZING ANTIBODY; TICK BORNE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY PERSISTENCE; ANTIBODY TITER; ARTICLE; CHILD; CHILD HEALTH CARE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; HEMATOMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MULTICENTER STUDY; MYALGIA; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SCHOOL CHILD; SERODIAGNOSIS; SEROPREVALENCE; SINGLE BLIND PROCEDURE; SKIN REDNESS; SLEEP DISORDER; SYSTEMIC DISEASE; TICK BORNE ENCEPHALITIS; VACCINATION; VIRUS STRAIN;

CHILD; CHILD, PRESCHOOL; ENCEPHALITIS VIRUSES, TICK-BORNE; ENCEPHALITIS, TICK-BORNE; FEMALE; HUMANS; INFANT; MALE; PROSPECTIVE STUDIES; VACCINATION; VIRAL VACCINES;

EID: 84863662134     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20058     Document Type: Article

References (23)

1. Haglund M, Günther G. Tick-borne encephalitis-pathogenesis, clinical course and long-term follow-up. Vaccine 2003; 21(Suppl 1):S11-8; PMID:12628810; http://dx.doi.org/10.1016/S0264-410X(02)00811-3.
2. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet 2008; 371:1861-71; PMID:18514730; http://dx.doi.org/10.1016/S0140-6736(08)60800-4.
3. Brauchli YB, Gittermann M, Michot M, Krähenbühl S, Gnehm HE. A fatal tick bite occurring during the course of tick-borne encephalitis vaccination. Pediatr Infect Dis J 2008; 27:363-5; PMID:18316981; http://dx.doi.org/10.1097/INF.0b013e318162a18e.
4. Schmolck H, Maritz E, Kletzin I, Korinthenberg R. Neurological, neuropsychological and electroencephalographic findings after European tick-borne encephalitis in children. J Child Neurol 2005; 20:506-8.
5. Fritsch P, Gruber-Sedlmayr U, Pansi H, Zöhrer B, Mutz I, Spork D, et al. Tick-borne encephalitis in Styrian children from 1981 to 2005: a retrospective study and a review of the literature. Acta Paediatr 2008; 97:535-8; PMID:18394095; http://dx.doi.org/10.1111/j.1651-2227.2008.00763.x.
6. Logar M, Arnez M, Kolbl J, Avsic-Zupanc T, Strle F. Comparison of the epidemiological and clinical features of tick-borne encephalitis in children and adults. Infection 2000; 28:74-7; PMID:10782391; http://dx.doi.org/10.1007/ s150100050050.
7. Loew-Baselli A, Poellabauer EM, Pavlova BG, Fritsch S, Firth C, Petermann R, et al. Prevention of tickborne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme. Vaccine 2011; 29:7307-19; PMID:21843576; http://dx.doi.org/10.1016/j.vaccine.2011.07.089.
8. Holbrook MR, Shope RE, Barrett AD. Use of recombinant E protein domain III-based enzyme-linked immunosorbent assays for differentiation of tick-borne encephalitis serocomplex flaviviruses from mosquito-borne flaviviruses. J Clin Microbiol 2004; 42:4101-10; PMID:15364996; http://dx.doi.org/10.1128/JCM.42.9. 4101-4110.2004.
9. Ecker M, Allison SL, Meixner T, Heinz FX. Sequence analysis and genetic classification of tick-borne encephalitis viruses from Europe and Asia. J Gen Virol 1999; 80:179-85; PMID:9934700.
10. Bröker M, Schöndorf I. Are tick-borne encephalitis vaccines interchangeable? Expert Rev Vaccines 2006; 5:461-6; PMID:16989626; http://dx.doi.org/10.1586/14760584.5.4.461.
11. Wittermann C, Schöndorf I, Gniel D. Antibody response following administration of two paediatric tick-borne encephalitis vaccines using two different vaccination schedules. Vaccine 2009; 27:1661-6; PMID:18940221; http://dx.doi.org/10.1016/j.vaccine.2008.10.003.
12. Wittermann C, Nicolay U, Hilbert AK, Schoendorf I. Paediatric tick-borne encephalitis (TBE) vaccines: schedules to optimize protection. Int J Med Microbiol 2008; 298(Suppl 1):301-4; http://dx.doi.org/10.1016/j.ijmm.2008.01. 002.
13. Pöllabauer EM, Pavlova BG, Löw-Baselli A, Fritsch S, Prymula R, Angermayr R, et al. Comparison of immunogenicity and safety between two paediatric TBE vaccines. Vaccine 2010; 28:4680-5; PMID:20433803; http://dx.doi.org/10.1016/j.vaccine.2010.04.047.
14. Barrett PN, Plotkin SA, Ehrlich H. Tick-borne encephalitis virus vaccine In: Plotkin SA, Orenstein WA, & Offit P, eds. Vaccines. Saunders Elsevier, 2008: 841-856.
15. Pöllabauer EM, Fritsch S, Pavlova BG, Löw-Baselli A, Firth C, Koska M, et al. Clinical evaluation to determine the appropriate paediatric formulation of a tick-borne encephalitis vaccine. Vaccine 2010; 28:4558-65; PMID:20452432; http://dx.doi.org/10.1016/j.vaccine.2010.04.075.
16. Holzmann H, Heinz FX, Mandl CW, Guirakhoo F, Kunz C. A single amino acid substitution in envelope protein E of tick-borne encephalitis virus leads to attenuation in the mouse model. J Virol 1990; 64:5156-9; PMID:2398538.
17. ICH-GCP guidelines. CPMP 2002.
18. Declaration of Helsinki. 2004. World Medical Association. Available from: http://www.wma.net/e/ethicsunit/helsinki.htm
19. Adner N, Leibl H, Enzersberger O, Kirgios M, Wahlberg T. Pharmacokinetics of human tick-borne encephalitis virus antibody levels after injection with human tick-borne encephalitis immunoglobulin, solvent/detergent treated, FSME-BULIN S/D in healthy volunteers. Scand J Infect Dis 2001; 33:843-7; PMID:11760166; http://dx.doi.org/10.1080/00365540110027358.
20. Loew-Baselli A, Poellabauer EM, Pavlova BG, Fritsch S, Koska M, Bobrovsky R, et al. Seropersistence of tick-borne encephalitis antibodies, safety and booster response to FSME-IMMUN 0.5 ml in adults aged 18-67 years. Hum Vaccin 2009; 5:551-6; PMID:19430202; http://dx.doi.org/10.4161/hv.5.8.8571.
21. Kießig ST, Abler U, Risse P, Friedrich J, Heinz F, Kunz C. Problems of cut-off level determination in enzyme immunoassays: the case of TBE-ELISA. Klin Lab 1993; 11:877-86. (Pubitemid 23349774)
22. Common Toxicity Criteria. Version 2.0, 30 April 1999. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcv20-4-30-992.pdf.
23. Michael Marcy S, Kohl KS, Dagan R, Nalin D, Blum M, Jones MC, et al.; Brighton Collaboration Fever Working Group. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004; 22:551-6; PMID:14741143; http://dx.doi.org/10.1016/ j.vaccine.2003.09.007.